Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association

Journal

Publication Venue For

  • Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial.  91:26-30. 2022
  • Sexually Transmitted Infections Among Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large Integrated Health System-A Cohort Study.  91:1-8. 2022
  • Association of PTSD With Longitudinal COVID-19 Burden in a Mixed-Serostatus Cohort of Men and Women: Weathering the Storm.  90:567-575. 2022
  • Asymptomatic SARS-CoV-2 Infection Is Common among ART-Treated People with HIV.  90:377-381. 2022
  • Factors Associated with Severity of COVID-19 Disease in a Multicenter Cohort of People with HIV in the United States, March-December 2020.  90:369-376. 2022
  • Polypharmacy Is Associated with Falls in Women with and Without HIV.  90:351-359. 2022
  • Using Implementation Mapping to Ensure the Success of PrEP Optimization Through Enhanced Continuum Tracking (PrOTECT) AL -A Structural Intervention to Track the Statewide PrEP Care Continuum in Alabama.  90:S161-S166. 2022
  • Insomnia and Risk of Myocardial Infarction Among People With HIV.  90:50-55. 2022
  • Development and Validation of a Model for Prediction of End-Stage Liver Disease in People with HIV.  89:396-404. 2022
  • Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women with HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence.  89:310-317. 2022
  • Differential Associations Between BDNF and Memory Across Older Black and White Adults With HIV Disease.  89:129-135. 2022
  • Mental Health Mediates the Association Between Gender-Based Violence and HIV Treatment Engagement in US Women.  89:151-158. 2022
  • SARS-CoV-2 infection among people living with HIV compared with people without HIV: Survey results from the MACS-WIHS combined cohort study.  89:1-8. 2022
  • Stigma determines antiretroviral adherence in adults with HIV in Myanmar.  89:19-26. 2022
  • Prevalence of COVID-19-Related Social Disruptions and Effects on Psychosocial Health in a Mixed-Serostatus Cohort of Men and Women.  88:426-438. 2021
  • Brief Report: COVID-19 Testing, Characteristics, and Outcomes among People Living with HIV in an Integrated Health System.  88:1-5. 2021
  • Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans with HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.  88:86-95. 2021
  • Suspected Immune-Related Adverse Events with an Anti-PD-1 Inhibitor in Otherwise Healthy People with HIV.  87:234-236. 2021
  • Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis among Adolescent Girls.  87:944-950. 2021
  • Referral Linkage to Preexposure Prophylaxis Care and Persistence on Preexposure Prophylaxis in an Integrated Health Care System.  87:918-927. 2021
  • High Frequency of Recurrent Falls among Prefrail and Frail Women with and Without HIV.  87:842-850. 2021
  • Secular Trends in Breast Cancer Risk Among Women With HIV Initiating ART in North America.  87:663-670. 2021
  • Types of Stroke among People Living with HIV in the United States.  86:568-578. 2021
  • Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097.  85:626-634. 2020
  • Longitudinal Assessment of Changes in Mental and Sexual Health Outcomes Due to COVID-19 among Latinx SMM and TGW.  85:E90-E92. 2020
  • Predicting Sexually Transmitted Infections among HIV+ Adolescents and Young Adults: A Novel Risk Score to Augment Syndromic Management in Eswatini.  85:543-552. 2020
  • Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.  85:498-506. 2020
  • Sexual behaviors after prep discontinuation among HIV serodiscordant couples in kenya and uganda.  85:174-181. 2020
  • Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110).  84:70-77. 2020
  • An Exploratory Study of Correlates of Allostatic Load in Older People Living with HIV.  83:441-449. 2020
  • Impaired Cognition Predicts Falls Among Women With and Without HIV Infection.  83:301-309. 2020
  • High Rates of Biomarker-Confirmed Alcohol Use among Pregnant Women Living with HIV in South Africa and Uganda.  82:443-451. 2019
  • PrEP Discontinuation and Prevention-Effective Adherence: Experiences of PrEP Users in Ugandan HIV Serodiscordant Couples.  82:265-274. 2019
  • The Impact of Cumulative Depression Along the HIV Care Continuum in Women Living with HIV during the Era of Universal Antiretroviral Treatment.  82:225-233. 2019
  • Internalized HIV Stigma Is Associated with Concurrent Viremia and Poor Retention in a Cohort of US Patients in HIV Care.  82:116-123. 2019
  • Brief Report: Aging Attenuates the Association between Coronary Artery Calcification and Bone Loss among HIV-Infected Persons.  82:46-50. 2019
  • Differentiated Care Preferences of Stable Patients on Antiretroviral Therapy in Zambia: A Discrete Choice Experiment.  81:540-546. 2019
  • High Incidence of Intended Partner Pregnancy Among Men Living With HIV in Rural Uganda: Implications for Safer Conception Services.  81:497-507. 2019
  • Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.  81:572-577. 2019
  • Establishing Dosing Recommendations for Efavirenz in HIV/TB-Coinfected Children Younger Than 3 Years.  81:473-480. 2019
  • Increasing Levels of Serum Heat Shock Protein 70 Precede the Development of AIDS-Defining Non-Hodgkin Lymphoma among Carriers of HLA-B8-DR3.  81:266-273. 2019
  • Detecting Disengagement from HIV Care before It Is Too Late: Development and Preliminary Validation of a Novel Index of Engagement in HIV Care.  81:145-152. 2019
  • Marijuana Use Is Not Associated with Changes in Opioid Prescriptions or Pain Severity among People Living with HIV and Chronic Pain.  81:231-237. 2019
  • Religiosity, Social Support, and Ethnic Identity: Exploring "resilience Resources" for African-American Women Experiencing HIV-Related Stigma.  81:175-183. 2019
  • Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART.  81:E6-E9. 2019
  • Brief Report: PrEP Eligibility among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability.  80:527-532. 2019
  • Buffering Internalization of HIV Stigma: Implications for Treatment Adherence and Depression.  80:284-291. 2019
  • Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions among People with HIV and Substance Use Disorder: Beyond Electronic Health Record Data.  80:330-341. 2019
  • Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals with Sustained Virological Suppression on Antiretroviral Therapy.  80:292-300. 2019
  • Role of sociobehavioral factors in subprotective TFV-DP Levels among YMSM Enrolled in 2 PrEP Trials.  80:160-165. 2019
  • Associations between multiple forms of discrimination and tobacco use among people living with HIV: The mediating role of avoidance coping.  78:9-15. 2019
  • Internal Working Models of Attachment Relationships and HIV Outcomes among Women Living with HIV.  80:E1-E8. 2019
  • Brief report: The association of chronic pain and long-term opioid therapy with HIV treatment outcomes.  79:77-82. 2018
  • A Social Network Analysis of HIV Treatment Partners and Patient Viral Suppression in Botswana.  78:183-192. 2018
  • Use of Nonantiretroviral Medications That May Impact Neurocognition: Patterns and Predictors in a Large, Long-Term HIV Cohort Study.  78:202-208. 2018
  • Experienced HIV-Related Stigma in Health Care and Community Settings: Mediated Associations With Psychosocial and Health Outcomes.  77:257-263. 2018
  • Intimate Partner Violence and Self-Reported Pre-exposure Prophylaxis Interruptions Among HIV-Negative Partners in HIV Serodiscordant Couples in Kenya and Uganda.  77:154-159. 2018
  • Assessing the association between changing NRTIs when initiating second-line ART and treatment outcomes.  77:413-416. 2018
  • HIV Continuum of Care for Youth in the United States.  77:110-117. 2018
  • Partner Notification for Youth Living With HIV in 14 Cities in the United States.  77:46-52. 2018
  • PrEP Use During Periods of HIV Risk Among East African Women in Serodiscordant Relationships.  77:41-45. 2018
  • Stigma reduction among African American women With HIV: UNITY health study.  78:269-275. 2018
  • " i Did Not Want to Give Birth to a Child Who has HIV ": Experiences Using PrEP during Pregnancy among HIV-Uninfected Kenyan Women in HIV-Serodiscordant Couples.  76:259-265. 2017
  • HIV Care Initiation Delay among Rural Residents in the Southeastern United States, 1996 to 2012.  76:171-176. 2017
  • Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared with the General Population.  75:568-576. 2017
  • Brief Report: IL-1β Levels Are Associated with Chronic Multisite Pain in People Living with HIV.  75:e99-e103. 2017
  • Budgetary impact of compliance with sti screening guidelines in persons living with HIV.  74:303-308. 2017
  • Higher cystatin c levels are associated with neurocognitive impairment in older HIV+ adults.  74:243-249. 2017
  • Elevated markers of vascular remodeling and arterial stiffness are associated with neurocognitive function in older HIV+ adults on suppressive antiretroviral therapy.  74:134-141. 2017
  • An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.  74:21-29. 2017
  • Association between internalized HIV-related stigma and HIV care visit adherence.  76:482-487. 2017
  • Brief Report: Factors Associated with the Selection of Initial Antiretroviral Therapy from 2009 to 2012.  74:60-64. 2017
  • Brief Report: Interpersonal and Intrapersonal Factors as Parallel Independent Mediators in the Association between Internalized HIV Stigma and ART Adherence.  74:e18-e22. 2017
  • Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access among African American Men, Women, and MSM in the Deep South.  74:56-59. 2017
  • Context matters: PrEP adherence is associated with sexual behavior among HIV serodiscordant couples in East Africa.  76:488-492. 2017
  • Counseling framework for HIV-serodiscordant couples on the integrated use of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention.  74:S15-S22. 2017
  • Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.  74:38-43. 2017
  • Hormonal contraception is not associated with reduced art effectiveness among women initiating art: Evidence from longitudinal data.  75:91-96. 2017
  • The relationship between efavirenz as initial antiretroviral therapy and suicidal thoughts among HIV-infected adults in routine care.  76:402-408. 2017
  • First-in-human trial of MIV-150 and zinc acetate coformulated in a carrageenan gel: Safety, pharmacokinetics, acceptability, adherence, and pharmacodynamics.  73:489-496. 2016
  • Heavy alcohol use is associated with worse retention in HIV care.  73:419-425. 2016
  • Improving depression among HIV-infected adults: Transporting the effect of a Depression Treatment Intervention to Routine Care.  73:482-488. 2016
  • Higher time-updated body mass index: Association with improved CD4+ cell recovery on HIV treatment.  73:197-204. 2016
  • Single viral load measurements overestimate stable viral suppression among HIV patients in care: Clinical and public health implications.  73:205-212. 2016
  • Poorly controlled HIV infection: An independent risk factor for liver fibrosis.  72:437-443. 2016
  • An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women.  72:333-343. 2016
  • Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.  72:289-296. 2016
  • Mechanisms for the negative effects of internalized HIV-related stigma on antiretroviral therapy adherence in women: The mediating roles of social isolation and depression.  72:198-205. 2016
  • When to monitor CD4 cell count and HIV RNA to reduce mortality and aids-defining illness in virologically suppressed hiv-positive persons on antiretroviral therapy in high-income countries: A prospective observational study.  72:214-221. 2016
  • Barriers to routine HIV testing in healthcare settings and potential solutions from the get tested Coachella valley campaign.  71:e127-e128. 2016
  • Enhanced allogeneic cellular responses to mismatched HLA-B antigens results in more efficient killing of HIV infected cells.  71:493-497. 2016
  • Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis.  71:287-294. 2016
  • HIV-infected ugandan women on antiretroviral therapy maintain HIV-1 RNA suppression across periconception, pregnancy, and postpartum periods.  71:399-406. 2016
  • Oral lopinavir use and human papillomavirus infection in HIV-positive women.  70:e63-e66. 2015
  • Enhanced recognition of HIV-1 cryptic epitopes restricted by HLA Class I alleles associated with a favorable clinical outcome.  70:1-8. 2015
  • Effects of Antenatal Care and HIV Treatment Integration on Elements of the PMTCT Cascade: Results from the SHAIP Cluster-Randomized Controlled Trial in Kenya.  69:e172-e181. 2015
  • Implementation and Operational Research: Effect of Integration of HIV Care and Treatment into Antenatal Care Clinics on Mother-to-Child HIV Transmission and Maternal Outcomes in Nyanza, Kenya: Results from the SHAIP Cluster Randomized Controlled Trial.  69:e164-e171. 2015
  • An Algorithm Approach to Determining Smoking Cessation Treatment for Persons Living With HIV/AIDS: Results of a Pilot Trial.  69:291-298. 2015
  • Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration.  69:348-354. 2015
  • Immune reconstitution but persistent activation after 48 weeks of antiretroviral therapy in youth with pre-therapy CD4 >350 in ATN 061.  69:52-60. 2015
  • Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract.  68:511-518. 2015
  • Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.  68:e84-e87. 2015
  • Clinic-wide intervention lowers financial risk and improves revenue to HIV clinics through fewer missed primary care visits.  68:472-476. 2015
  • Impact of age on retention in care and viral suppression.  68:413-419. 2015
  • Estimating the cost of increasing retention in care for HIV-infected patients: Results of the CDC/HRSA retention in care trial.  68:345-350. 2015
  • Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States.  68:169-177. 2015
  • Phase 1 safety, pharmacokinetics, and pharmacodynamics of dapivirine and maraviroc vaginal rings: A double-blind randomized trial.  70:242-249. 2015
  • Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study.  69:439-445. 2015
  • Depression during pregnancy and the postpartum among HIV-infected women on antiretroviral therapy in Uganda.  67:S179-S187. 2014
  • Eliminating preventable HIV-related maternal mortality in Sub-Saharan Africa: What do we need to know?.  67:S250-S258. 2014
  • HIV-positive status disclosure and use of essential PMTCT and maternal health services in rural Kenya.  67:S235-S242. 2014
  • Lost opportunities to reduce periconception HIV transmission: Safer conception counseling by South African providers addresses perinatal but not sexual HIV transmission.  67:S210-S217. 2014
  • High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.  67:91-97. 2014
  • Genital tract HIV RNA levels and their associations with human papillomavirus infection and risk of cervical precancer.  66:316-323. 2014
  • Antiviral activity of genital tract secretions after oral or topical tenofovir pre-exposure prophylaxis for HIV-1.  66:65-73. 2014
  • Factors associated with delayed hepatitis b viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort.  66:96-101. 2014
  • Antiretroviral therapy restores age-dependent loss of resting memory B cells in young HIV-Infected zambian children.  65:505-509. 2014
  • Pregnancy Intentions Among Women Living With HIV in the United States.  65:306-311. 2014
  • A prospective study of the effect of pregnancy on CD4 counts and plasma HIV-1 RNA concentrations of antiretroviral-naive HIV-1-infected women.  65:231-236. 2014
  • Characterization of T-Cell responses to cryptic epitopes in recipients of a noncodon-optimized HIV-1 Vaccine.  65:142-150. 2014
  • The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment.  65:190-197. 2014
  • Addressing standards of care in resource-limited settings.  65. 2014
  • Changes in cellular immune activation and memory T-cell subsets in HIV-infected Zambian children receiving HAART.  67:455-462. 2014
  • Increased left ventricular posterior wall end-diastolic thickness in adolescents with delayed diagnosis of vertically acquired HIV infection.  66. 2014
  • Managing multiple funding streams and agendas to achieve local and global health and research objectives: Lessons from the field.  65. 2014
  • Raltegravir pharmacokinetics in neonates following maternal dosing.  67:310-315. 2014
  • Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care.  64:254-260. 2013
  • Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.  64:167-173. 2013
  • Global maternal and child health goals will not be achieved without addressing HIV-related stigma.  64. 2013
  • High levels of antiretroviral use and viral suppression among persons in HIV care in the United States, 2010.  63:299-306. 2013
  • Hematologic, hepatic, renal, and lipid laboratory monitoring after initiation of combination antiretroviral therapy in the united states, 2000-2010.  63:216-220. 2013
  • Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: Final 5-year results from STARTMRK.  63:77-85. 2013
  • Erratum: Pain, mood, and substance abuse in HIV: Implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure (Journal of Acquired Immune Deficiency Syndromes (2012) 61 (164-170).  63. 2013
  • Fertility intentions and interest in early antiretroviral therapy among east African HIV-1-infected individuals in serodiscordant partnerships.  63. 2013
  • Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.  63:59-66. 2013
  • Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation.  62:505-508. 2013
  • Invasive cervical cancer risk among HIV-infected women: A North American multicohort collaboration prospective study.  62:405-413. 2013
  • The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men.  62:447-456. 2013
  • Retention among North American HIV-infected persons in clinical care, 2000-2008.  62:356-362. 2013
  • Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: A north american cross cohort analysis.  62:149-163. 2013
  • Multimorbidity patterns in HIV-infected patients: The role of obesity in chronic disease clustering.  61:600-605. 2012
  • Prevalence of proteinuria and elevated serum cystatin c among hiv-infected adolescents in the reaching for Excellence in Adolescent Care and Health (REACH) study.  61:499-506. 2012
  • Pain, mood, and substance abuse in HIV: Implications for clinic visit utilization, antiretroviral therapy adherence, and virologic failure.  61:164-170. 2012
  • Six-month hemoglobin concentration and its association with subsequent mortality among adults on antiretroviral therapy in Lusaka, Zambia.  61:120-123. 2012
  • Willingness of Kenyan HIV-1 serodiscordant couples to use antiretroviral-based HIV-1 prevention strategies.  61:116-119. 2012
  • HIV and aging: State of knowledge and areas of critical need for research. a report to the NIH office of AIDS research by the HIV and aging working group.  60. 2012
  • Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: Pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials.  60:33-42. 2012
  • Childhood trauma and health outcomes in HIV-infected patients: An exploration of causal pathways.  59:409-416. 2012
  • Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.  59:245-252. 2012
  • Early retention in HIV care and viral load suppression: Implications for a test and treat approach to HIV prevention.  59:86-93. 2012
  • Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.  58:475-481. 2011
  • Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.  58:253-260. 2011
  • Interleukin-2 production by polyfunctional HIV-1-specific CD8 T cells is associated with enhanced viral suppression.  58:132-140. 2011
  • Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe.  57:157-164. 2011
  • Prevention of mother-to-child transmission of HIV in Thailand: Physicians' attitudes on zidovudine use, pregnancy termination, and willingness to provide care.  21:217-222. 1999
  • Declining CD4+ T-lymphocyte counts are associated with increased risk of enteric parasitosis and chronic diarrhea: Results of a 3-year longitudinal study.  20:154-159. 1999
  • Erratum: Serum retinol and HIV-1 RNA viral load in rapid and slow progressors (Journal of Acquired Immune Deficiency and Human Retrovirology (1998) 18 (21-26)).  18:401-406. 1998
  • Serum retinol and HIV-1 RNA viral load in rapid and slow progressors..  18:401-406. 1998
  • Serum retinol and HIV-1 RNA viral load in rapid and slow progressors.  18:21-26. 1998
  • Polyamine pools in HIV-infected cells.  17:101-103. 1998
  • Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-α2a in patients with HIV.  16:247-253. 1997
  • Rapid and selective depletion of CD4+ T lymphocytes and preferential loss of memory cells on interaction of mononuclear cells with HIV-1 glycoprotein-expressing cells.  16:74-82. 1997
  • Maternal serum vitamin A levels are not associated with mother-to-child transmission of HIV-1 in the United States.  14:321-326. 1997
  • Complement activation by HIV-1-infected cells: The role of transmembrane glycoprotein gp41.  14:102-109. 1997
  • Assessment of antiretroviral therapy by plasma viral load testing: Standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared.  10:139-149. 1995
  • Zidovudine for the prevention of vertical HIV transmission: A decision analytic approach.  9:401-407. 1995
  • Issues in combination antiretroviral therapy: A review.  7:S24-S37. 1994
  • Pathogenicity and diversity of hiv and implications for clinical management: A review.  7:S2-S11. 1994
  • International Standard Serial Number (issn)

  • 1077-9450
  • 1525-4135
  • Electronic International Standard Serial Number (eissn)

  • 1077-9450